You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):眾生睿創穫得一類創新藥RAY1225注射液III期臨牀試驗倫理批件
格隆匯 02-27 17:57

格隆匯2月27日丨眾生藥業(002317.SZ)公佈,近日,廣東眾生藥業股份有限公司控股子公司廣東眾生睿創生物科技有限公司(簡稱“眾生睿創”)自主研發的一類創新多肽藥物RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗(REBUILDING-2)獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件,批准項目開展。

RAY1225注射液是眾生睿創研發的、具有全球自主知識產權的創新結構多肽藥物,屬於長效GLP-1類藥物,具有GLP-1受體和GIP受體雙重激動活性,可通過刺激胰島素分泌、延緩胃排空等機制調節人體代謝和控制血糖,有望用於降糖、減肥、代謝綜合徵等多種代謝性疾病的治療。

本次RAY1225注射液治療超重/肥胖參與者的III期臨牀試驗組長單位倫理批件的獲得,標誌着RAY1225注射液III期臨牀試驗將全面啟動。眾生睿創將在全國主要研究者的帶領下,按照相關要求高質量、加速度、科學規範地推進III期臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account